MIRM — Mirum Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $5.47bn
- $5.40bn
- $521.31m
- 85
- 10
- 85
- 64
Annual income statement for Mirum Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 19.1 | 77.1 | 186 | 337 | 521 |
| Cost of Revenue | |||||
| Gross Profit | 17.2 | 64.7 | 139 | 255 | 421 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 84.6 | 208 | 345 | 424 | 543 |
| Operating Profit | -65.4 | -131 | -158 | -87.6 | -22.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -84 | -142 | -162 | -86.9 | -21.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -84 | -136 | -163 | -87.9 | -23.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -84 | -136 | -163 | -87.9 | -23.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -84 | -136 | -163 | -87.9 | -23.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.09 | -4.01 | -3.22 | -1.85 | -0.465 |